Revenues in Q4 came in at SEK10m, slightly softer than we had estimated, albeit still showing growth, mainly in Germany.
Redeye's provides its initial take on Oncopeptides’ year-end report, which came in slightly softer than we had estimated, albeit still showi...
Redeye comments on the positive results from a US study of melfufen in the intended target population, which demonstrated a good safety prof...
Redeye provides a brief comment on Pepaxti's market access in Italy.
Redeye comments on Oncopeptides Q3 report 2024. Revenues in Q3 increased slightly compared to Q2, but product sales declined.
Redeye comments on Oncopeptides’ licensing deal for Pepaxti in South Korea.
Redeye provides a brief comment on the selection of a new drug candidate.
Redeye comments on Oncopeptides' Q1 report, which had few surprises in terms of financials.
Redeye comments on the outcome of Oncopeptide's rights issue.
Redeye comments on the decision of NICE not to recommend Pepaxti in the UK, which is not unexpected.
Redeye initiates coverage of Oncopeptides, a commercial-stage biotech company focusing on multiple myeloma.
